Cardiol Therapeutics Inc.
NASDAQ:CRDLDrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $114.64M
- Beta
- 0.80
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.31M
Average 0.68M
CRDL Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Cardiol Therapeutics Inc.NASDAQ: CRDL
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q1 FY2026 other income / expenses was -CA$1.11M, compared with CA$141.41K a year earlier. Trailing-twelve-month other income / expenses was -CA$758.66K. Over 3 fiscal years it compounded at -59.8% a year.
Context
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -CA$1.11M or moves back toward the trailing-twelve-month quarterly average of -CA$189.66K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
CAD · from the income statement
- Latest · FY2025
- 497.42K CAD
- Year-over-year change
- -86.2%
- 4-year CAGR
- -45.3%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 497.42K | -86.2% |
| FY2024 | 2024-12-31 | 3.6M | +187.9% |
| FY2023 | 2023-12-31 | 1.25M | -83.7% |
| FY2022 | 2022-12-31 | 7.68M | +38.2% |
| FY2021 | 2021-12-31 | 5.56M | — |
Other Income / Expenses vs competitors
How CRDL compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -120.8% is the 9th highest of 10, against a peer median of -42.2%.
- Over three fiscal years its annual growth of -59.8% compares with a peer median of +15.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IMAImageneBio Inc | LTM Mar 2026 | $10.53M USD | +5.4% | +8.8% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $3.53M USD | +1344.0% | — | — |
| FY2025 | $2.79M USD | -60.4% | +22.4% | 4360.9% | |
| LTM Mar 2026 | $1.83M USD | +210.7% | +142.0% | 1742.9% | |
| LTM Mar 2026 | $727K USD | -42.2% | -49.5% | — | |
| LTM Mar 2026 | -$38K USD | -101.2% | +28.6% | 0.2% | |
| LTM Mar 2026 | -€440.14K EUR | -104.4% | -1.4% | 1500.6% | |
| LTM Mar 2026 | -CA$758.66K CAD | -120.8% | -59.8% | — | |
| LTM Mar 2026 | -$12.7M USD | -581.9% | — | 12.4% | |
| LTM Jun 2025 | -₪19.09M ILS | +51.3% | — | 7.9% | |
| Peer median (excluding CRDL) | — | -42.2% | +15.6% | 756.5% | |
Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 62.27K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 174.26K | 162.23K | 187.38K | 0 | 0 |
| Gross Profit | (112K) | (162.23K) | (187.38K) | 0 | 0 |
| Gross Margin | -179.9% | — | — | — | — |
| Research & Development | 8.59M | 13.99M | 10.73M | 14.01M | 14.02M |
| Selling, General & Admin | 21.86M | 16.34M | 11.55M | 25.89M | 20.2M |
| Operating Expenses | 30.46M | 30.33M | 22.29M | 40.28M | 34.32M |
| Depreciation & Amortization | 174.26K | 162.23K | 187.38K | 162.11K | 101.98K |
| EBITDA | (24.84M) | (22.66M) | (21.04M) | (36.52M) | (33.72M) |
| EBITDA Margin | -39891.0% | — | — | — | — |
| Operating Income | (30.57M) | (30.49M) | (22.47M) | (40.28M) | (34.32M) |
| Operating Margin | -49092.4% | — | — | — | — |
| Interest Income | 106K | 1.24M | 2.04M | 1.19M | 726.4K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.56M | 7.68M | 1.25M | 3.6M | 497.42K |
| Income Before Tax | (25.01M) | (22.82M) | (21.22M) | (36.68M) | (33.82M) |
| Pre-Tax Margin | -40170.9% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (25.01M) | (22.82M) | (21.22M) | (36.68M) | (33.82M) |
| Net Margin | -40170.9% | — | — | — | — |
| EPS (Basic) | (0.73) | (0.49) | (0.44) | (0.51) | (0.39) |
| EPS (Diluted) | (0.73) | (0.49) | (0.44) | (0.51) | (0.39) |
| Weighted Avg Shares | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
| Weighted Avg Shares (Diluted) | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
Cardiol Therapeutics Inc.
NASDAQ:CRDL
Intrinsic Alpha fair value
Locked
Current Price
$0.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.